Financial News

J&J’s 2Q Pharma Sales Up 17%

STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 2Q Revenues: $23.3 billion (+27%) 2Q Earnings: $6.3 billion (+73%) Comments: Pharmaceutical sales were up 17% to $12.6 billion in the quarter, driven by STELARA for the treatment of immune-mediated inflammatory diseases, up 34% to $2.3 billion; DARZALEX for the treatment of multiple myeloma, up 59% to $1.4 billion; TREMFYA (guselkumab) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis, up 40% to $479 million; ERLEADA (apalutamide), f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters